<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248404</url>
  </required_header>
  <id_info>
    <org_study_id>CR-TSC-001</org_study_id>
    <nct_id>NCT00248404</nct_id>
    <nct_alias>NCT00255736</nct_alias>
  </id_info>
  <brief_title>NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)</brief_title>
  <official_title>A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kiadis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kiadis Pharma</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment
      of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal,
      bladder, breast, and lung cancers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability of NB1011 infusions</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of maximum tolerated dose (MTD)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of NB1011 and its metabolite</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical activity as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of TS overexpression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NB1011</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced, recurrent, or metastatic solid tumors

          -  TS overexpression (&gt; 4 by reverse transcription polymerase chain reaction [RT-PCR]) in
             archival and fresh samples

          -  Suitable for experimental monotherapy

          -  Measurable disease

        Exclusion Criteria:

          -  Tumors that cannot be biopsied or with low level of TS expression

          -  Requirement for concomitant anticancer therapy

          -  Treatment with another investigational product within 30 days of study entry

          -  Pregnant or lactating women

          -  Active or uncontrolled serious bacterial, viral, fungal, or parasitic infection.

          -  HIV infection

          -  Clinically apparent meningeal or central nervous system (CNS) metastases or
             carcinomatous meningitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neuteboom ST, Karjian PL, Boyer CR, Beryt M, Pegram M, Wahl GM, Shepard HM. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction. Mol Cancer Ther. 2002 Apr;1(6):377-84.</citation>
    <PMID>12477050</PMID>
  </reference>
  <reference>
    <citation>Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000 Apr;6(4):1322-7.</citation>
    <PMID>10778957</PMID>
  </reference>
  <reference>
    <citation>Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 1996 Jan;14(1):176-82.</citation>
    <PMID>8558194</PMID>
  </reference>
  <results_reference>
    <citation>Pegram M, Yeon CH, Ku N, Gottlieb C, Sheppard M, Cossum P, John E, Iqbal S, Garcia A, Lenz HJ. Enzyme Catalyzed Therapeutic Activation of NB1011 Selectively Targets Thymidylate Synthase-overexpressing Tumor Cells: Phase I Results. ASCO Meeting, New Orleans, June 4-8, 2004 (abstract 3144)</citation>
  </results_reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>September 26, 2012</last_update_submitted>
  <last_update_submitted_qc>September 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2012</last_update_posted>
  <keyword>colorectal cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>small bowel cancer</keyword>
  <keyword>Advanced, recurrent, or metastatic solid tumors of any type</keyword>
  <keyword>TS overexpression confirmed by fresh biopsy (RTPCR)</keyword>
  <keyword>Suitable for experimental monotherapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

